A Safety and Immunogenicity Study of IVACFLU-A/H5N1
Condition: Avian InfluenzaInterventions: Biological: A/H5N1 vaccine; Biological: Placebo ComparatorSponsors: Institute of Vaccines and Medical Biologicals, Vietnam; National Institute of Hygiene and Epidemiology, Vietnam; World Health Organization; Department of Health and Human Services; PATH; FHI 360Not yet recruiting - verified October 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2015 Category: Research Source Type: clinical trials
Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study
Conclusions
Antibody levels declined substantially in all groups. Seroprotection rates, geometric mean titres for haemagglutination inhibition antibodies, and CD4+ T-cell responses tended to be higher in the AS03A-adjuvanted groups. There was no clear benefit, in terms of long-term persistence of the immune response, of doubling the dose of the adjuvanted vaccine. No safety concern was observed up to 24 months post-primary vaccination.
Trial registration
NCT00397215 (7 November 2006). (Source: Trials)
Source: Trials - October 29, 2014 Category: Research Source Type: clinical trials
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
Conditions: Influenza, Human; Flu, Human; Flu, Avian; Influenza; Influenza A Virus, H5N1 SubtypeInterventions: Biological: Novartis Investigational H5N1 vaccine; Biological: Novartis Investigational H5N1 vaccine; Biological: Novartis Seasonal Influenza Vaccine; Biological: Novartis Seasonal Influenza VaccineSponsors: Novartis; Novartis VaccinesRecruiting - verified May 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2014 Category: Research Source Type: clinical trials
